<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/027565E4-50E9-45A7-B48D-D81688C836CF"><gtr:id>027565E4-50E9-45A7-B48D-D81688C836CF</gtr:id><gtr:name>WaVe Biosciences</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/027565E4-50E9-45A7-B48D-D81688C836CF"><gtr:id>027565E4-50E9-45A7-B48D-D81688C836CF</gtr:id><gtr:name>WaVe Biosciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ACD6437C-C203-4D72-B0AF-9A502AB5C3BF"><gtr:id>ACD6437C-C203-4D72-B0AF-9A502AB5C3BF</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>McLean</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1310207A-56D8-481F-980E-4F4C60A5300F"><gtr:id>1310207A-56D8-481F-980E-4F4C60A5300F</gtr:id><gtr:firstName>Frances</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A51ABAD7-AD25-491A-BB9E-515BEF9F4166"><gtr:id>A51ABAD7-AD25-491A-BB9E-515BEF9F4166</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Campbell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801742"><gtr:id>5A1D82A4-901F-4C62-A01A-4ED92901C5F7</gtr:id><gtr:title>OPTIMISED DELIVERY OF THERAPEUTIC siRNA INTO HUMAN SKIN</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801742</gtr:grantReference><gtr:abstractText>RNAi is a new form of therapy that allows faulty genes to be switched off in a wide range of genetic diseases and in cancer. The barrier to applying this revolutionary new form of medicine is how to deliver it into the body, since the molecules involved are larger than normal drugs and so cells require some help in taking this material up so it can have its beneficial effect. The main aim of this project is to revolutionise the delivery of these new therapeutics into the skin, as a test organ system. Skin has the advantage of being on the outside of the body for easy access, and excess human skin from cosmetic surgery (breast reductions and tummy tucks) is readily available for experimentation to optimise delivery of RNAi molecules. In pursuit of this, we will develop an innovative new tool combining chemistry, ultrasound and arrays of microscopic painless needles for fast, effective and reliable delivery into skin at high coverage rates. Once optimised for skin diseases, this hand-held device will be readily adapted for use on internal organs using keyhole surgery methods, so that the potential applications of this device across all branches of medicine are huge. The team assembled in Dundee brings together leading molecular biologists with engineers, supported by further international collaborators with diverse skills across many different fields, in order to piece together elements of technology in ways that have never been done before. The estimated market for solving the therapy delivery problem being tackled here is in the order of 10s of billions of dollars per year.</gtr:abstractText><gtr:technicalSummary>RNA-interference (RNAi) has revolutionised biomedical sciences as a research tool and has enormous potential for treatment a host of genetic diseases and cancer. In 2004, the projected market for this new class of therapeutics was estimated at $25 billion in the USA alone. The major limiting factor preventing RNAi technology from clinical application is effective delivery. The skin is an attractive target organ for delivery development due its accessibility but the stratum corneum, the impermeable barrier layer at the epidermal surface, is difficult to cross. Here we have assembled a multidisciplinary team consisting of two molecular biologists with expertise in genetic skin disease and an physicist highly active in design of microfabrication of new medical devices for ultrasonic delivery of molecules (sonoporation), all based in a new translational research division within the 5* research environment at the University of Dundee. The team is supported by collaborators that include a clinical dermatologist, the CEO of a siRNA biopharma start-up and the leading experts in use of sonoporation for skin delivery and in use of microneedles for trans-stratum corneum delivery. The overarching objective for this project is to revolutionise the delivery of molecular therapeutics across the stratum corneum and into the underlying living tissue. In pursuit of this, we will develop an innovative new tool offering the critical capability for fast, effective and reliable delivery at coverage rates approaching square cm/sec, and all in a pain-free format. This will be achieved by marrying the latest cutting edge findings drawn from ultrasound driven micro-fluid mechanics, with state-of-the-art RNAi biotechnology. Here, we make a quantum leap in procedures by coupling the initial penetrative passage through the stratum corneum with an active mode of subsequent dispersal into the viable dermis using ultrasound activated microbubbles that contain the siRNA. Delivery testing will involve use of human skin biopsy material and an animal model. This hybrid technology has not been attempted before but holds great promise. Due to the activity building around RNAi therapeutics in the biotech industry, a window of opportunity to develop the first effective means of widespread RNAi delivery. If successful in skin, this technology could be readily adapted for laporascopic use in other organ systems. Truly multidisciplinary, high-risk, high potential return research of this nature is difficult to fund from a single source such as EPSRC, MRC etc and so the Milstein scheme is an ideal funding stream for this project.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>519025</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Roslin Institute</gtr:department><gtr:description>Roslin</gtr:description><gtr:id>6F8F9DEC-0E32-4A71-8A5C-B1AFF6BCEA24</gtr:id><gtr:impact>This collaboration is helping us optimise an ex vivo skin culture system. No final outcome yet.</gtr:impact><gtr:outcomeId>56e06b9e5fe6d9.72710482-1</gtr:outcomeId><gtr:partnerContribution>Provision of discarded pig skin following ova harvesting.</gtr:partnerContribution><gtr:piContribution>Developing systems for ex vivo culture of skin.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>WaVe Biosciences</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>WaVe</gtr:description><gtr:id>3F90B36B-F0B6-492A-981E-843AFDA1AE41</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>5462462487a4a8.07665054-1</gtr:outcomeId><gtr:partnerContribution>None as yet but we anticipate obtaining &amp;quot;stereopure&amp;quot; oligonucleotides for testing in 2015.</gtr:partnerContribution><gtr:piContribution>We established an informal collaboration with WaVe Biosciences in 2014 to test their proprietary &amp;quot;stereopure&amp;quot; antisense oligonucleotides using in vitro and in vivo model systems we have available.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open Doors Day, College of Life Sciences, Dundee</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>998A065D-B396-4B94-9ECC-42DA9A8A8408</gtr:id><gtr:impact>Attended College of Life Sciences Open Doors Day where scientists explain their research to a few hundred members of the general public.</gtr:impact><gtr:outcomeId>56e0995248d782.31186861</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scottish EBS Patient Support Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>937F8BE8-89BE-4459-BF46-78DE8517748B</gtr:id><gtr:impact>About 100 patients and family members with the inherited skin blistering disease epidermolysis bullosa simplex (EBS) attended a 1-day meeting to learn about the molecular basis of their disease and progress being made in therapy development.

The success of this meeting led to organisation of bigger meeting in the south of England (May 2012) and north of England (Nov 2012), with help from the EB charity, DEBRA.</gtr:impact><gtr:outcomeId>Wmzws4TNcNj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PC Project America Patient support meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>192B6E2A-80AD-48CE-8111-7201F065A3BD</gtr:id><gtr:impact>About 100 patients and family members affected by the skin disease pachyonychia congenita attended a 2 day workshop in North America, co-organised by members of the Dundee research group. These meetings are run every 2 years in the USA or Canada for the benefit of patients from the Americas.

Very positive feedback received from patients.</gtr:impact><gtr:outcomeId>KQGgHs4PPhc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2009,2011,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release, Wellcome Trust Strategic Award to Dundee Dermatology and Genetic Medicine</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>53417987-79CE-4B3F-8D6A-0BC8A69F6F12</gtr:id><gtr:impact>Media interviews about the Wellcome Trust's major funding boost for dermatology research at the University of Dundee
e.g. http://www.bbc.co.uk/news/uk-scotland-tayside-central-18883942</gtr:impact><gtr:outcomeId>56e09ad5b22515.18412400</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PC Project European Patient Support Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>62EE0EA4-4CCD-47A0-8D83-06793749483C</gtr:id><gtr:impact>About 100 patients and family members affected by the genetic skin disease pachyonychia congenita from all over Europe attended a 2 day meeting organised by this research group. This allowed close interaction of patients, family members, clinicians and scientists. This meeting is run every 2 years by the Dundee group and was hosted in Dundee in 2006, 2008 and in Edinburgh 2010, 2012, 2014.

Very positive feedback received from the patients and other attendees.</gtr:impact><gtr:outcomeId>SYtejxCNktw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2008,2010,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DEBRA UK research leadership visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0BC28CD6-D681-4D41-9B0C-24D414896113</gtr:id><gtr:impact>Visits from DEBRA UK Research Managers and lead fundraisers to laboratories, with updates on current research and future planning.</gtr:impact><gtr:outcomeId>56e075f1673419.54859844</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture, Comber Rotary Club, County Down, Northern Ireland.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>71CE95AC-D397-47F8-B254-539318014E35</gtr:id><gtr:impact>Public talk hosted by a Rotary Club. &amp;quot;Studying inherited skin disease through thick and thin&amp;quot;. Audience of about 30-40 Rotarians and interested public. 30 min lecture plus 15 min discussion.</gtr:impact><gtr:outcomeId>58ca53aa4596e9.18151263</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F0CFCB1F-F47C-4560-9BD8-2DA03EDA2F46</gtr:id><gtr:impact>65 people attended the public lecture.

Invited to do a follow-up lecture in 2014</gtr:impact><gtr:outcomeId>eTWDJoTjiad</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cafesciencedundee.co.uk/?p=1235</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Consultant Geneticist on Channel 4's &quot;Embarrassing Bodies&quot;</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>97C1ACF5-02BF-4CB6-8E01-4059BEF99BAD</gtr:id><gtr:impact>Consultant on Channel 4's &amp;quot;Embarrassing Bodies&amp;quot; in relation to an undiagnosed patient with pachyonychia congenita. Following this mass-media appearance, more than 50 new undiagnosed families with pachyonychia congenita or related conditions contacted the research group and were given genetic testing and patient support. The programme has been repeated in the UK and other nations worldwide, and each time, further undiagnosed families have come forth and been given genetic testing, contact with patient groups and other support. Many famililes contacted in this way have attended patient support meetings organised by the group.</gtr:impact><gtr:outcomeId>56e09a3eaf08c0.95875024</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK (South) Epidermolysis bullosa simplex patient support meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CAA57CCC-9A68-4E81-BA39-D31F528D6981</gtr:id><gtr:impact>About 100 patients with epidermolysis bullosa simplex (EBS) and their carers/families attended a 1 day meeting in Reading, co-organised by the Dundee group and the patient support organisation DEBRA. The purpose of this meeting was to update these individuals on the state of the art in relation to understanding the molecular basis of their disease and importantly, what therapies are in development.

None as yet.</gtr:impact><gtr:outcomeId>54624ccc1a8e36.04566640</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK (North) Epidermolysis bullosa simplex patient support meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A2C3BED8-654F-4BE0-B054-D5C336965D72</gtr:id><gtr:impact>More than 100 patients with the inherited skin blistering disorder epidermolysis bullosa simplex (EBS) attended 1-day meetings in Manchester, and in Dundee to learn about the molecular basis of their disease and hear about progress being made in therapy development.

These EBS patient meetings will now be an annual event, with 3 being held (Scotland, North of England, South of England) to cover the UK and allow patients to travel to the nearest venue.</gtr:impact><gtr:outcomeId>bY1CPNNg6pL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2012,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release about election to The Royal Society</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8F4CF0C4-927C-49FD-8C13-16B86D031F94</gtr:id><gtr:impact>Press release about election to The Royal Society:
http://www.dundee.ac.uk/news/2014/professor-irwin-mclean-elected-to-royal-society.php
Several press articles and local radio coverage</gtr:impact><gtr:outcomeId>56e09c061d7581.65714354</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/news/2014/professor-irwin-mclean-elected-to-royal-society.php</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pachyonychia congenita patient support, Hefei, China</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>808BA7C2-EBE5-4D36-ADB4-3B1BD6742B2A</gtr:id><gtr:impact>About 20 patients with pachyonychia congenita plus their attendant family members, clinicians and scientists, all from mainland China, attended the first patient support meeting for this disease in the Far East.

Positive feedbak received from Chinese patients, many of whom had never had a firm diagnosis or any real understanding of their disease. A number of patients were given genetic diagnosis as a result of this meeting and some misdiagnosed cases correctly reassigned.</gtr:impact><gtr:outcomeId>AeAN2wTmryM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DEBRA Annual Conference, Weybridge, UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BC1A2C03-1252-4753-B8E2-A8BDF5BB0BE6</gtr:id><gtr:impact>More than 100 patients with the inherited skin blistering disorder epidermolysis bullosa simplex (EBS) attended 1-day meetings in Weybridge, South of England, and Staffordshire, South of England, to learn about the molecular basis of their disease and hear about progress being made in therapy development.

Owing to the success of this meeting and the preceding one in Scotland, a follow-up meeting was organised to spread this information to patients in the north of England in November 2012. These EBS patient meetings will now be an annual event.</gtr:impact><gtr:outcomeId>abXx2nqxai5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2012,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Talk, South West Scotland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6F214FF8-8F99-476D-8959-C5A4FE63FE50</gtr:id><gtr:impact>By direct invitation, a 45 min presentation was given to about 100 members of the public involved in fund-raising for skin disease charities, particularly relating to the filaggrin gene in ichthyosis, common dry skin and eczema/allergy, as well as outlining our efforts to develop therapies based on this gene. Lengthy discussion followed - about 15 min formal and 2 hours informal.

Small financial donation to the lab was received from this group.</gtr:impact><gtr:outcomeId>PptJmqDtHM7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PC Project France Patient support meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>161EA697-CC91-47BE-A454-7F3FB76364C6</gtr:id><gtr:impact>About 50 French patients and family members affected by the skin disease pachyonychia congenita attended a 2 day French language workshop organised by members of the Dundee group. This will be a biannual meeting from now on, with the next one scheduled for 2012.

Very positive feedback obtained from the families. This is to be a bi-annual event, next meeting 2016.</gtr:impact><gtr:outcomeId>kN95jGhLzcE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Undergraduate Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41B45054-F418-4954-9DD3-CE3B3D58B06D</gtr:id><gtr:impact>Undergraduate Open Day, School of Life Sciences</gtr:impact><gtr:outcomeId>56e09ccd04fdf9.46600633</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PC Project European Patient Support Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C670E3E8-A750-415C-BE45-005A47965BEA</gtr:id><gtr:impact>More than 100 patients and family members affected by the skin disease pachyonychia congenita attended a 2 day meeting in Edinburgh organised by the Dundee research group.

Very positive feedback received from patients and their families. This is now a biannual event, with the next date set for Oct 2014.</gtr:impact><gtr:outcomeId>mPka7CS7cFk</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2006,2008,2010,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture (British Association for the Advancement of Science)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8E9F1D43-1C04-4339-AE34-AE214DE4BFF2</gtr:id><gtr:impact>&amp;quot;Are you thick skinned enough? Dermatology Discoveries in Dundee&amp;quot;. Audience of about 60 people, all from the Tayside region general public. 60 min lecture plus 30 min discussion.</gtr:impact><gtr:outcomeId>58ca532c002c50.93936941</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release regarding Buchanan Medal</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>71A80842-97E7-4D24-9340-1E38AF341E3B</gtr:id><gtr:impact>Press release on Buchannan Medal of the Royal Society, local and national press coverage
http://www.dundee.ac.uk/news/2015/professor-irwin-mclean-awarded-buchanan-medal-by-royal-society.php</gtr:impact><gtr:outcomeId>56e09d531d4136.70481615</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/news/2015/professor-irwin-mclean-awarded-buchanan-medal-by-royal-society.php</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>82258</gtr:amountPounds><gtr:country>Austria, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Fellowship</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Dystrophic Epidermolysis Bullosa Research Association (DEBRA)</gtr:fundingOrg><gtr:id>70F80541-9AD6-411B-93B0-F2D983446BEC</gtr:id><gtr:outcomeId>56e06ddc1e7487.58362906</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5869875</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Strategic Award</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>098439/Z/12/Z</gtr:fundingRef><gtr:id>5015560A-B1ED-443D-B3A6-FE1BFBBA0CB3</gtr:id><gtr:outcomeId>EM3dAdx9hp9</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>38500</gtr:amountPounds><gtr:country>Austria, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Dystrophic Epidermolysis Bullosa Research Association (DEBRA)</gtr:fundingOrg><gtr:id>BB40D547-3708-49B4-89E0-A7E4C2D2DF52</gtr:id><gtr:outcomeId>56e06e465aacb9.15871000</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1426740</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0802780</gtr:fundingRef><gtr:id>38B0389B-F64D-4722-87E5-CF6B7A2AEE83</gtr:id><gtr:outcomeId>T2WjEXWdt1J0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>169773</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:fundingRef>1450/1</gtr:fundingRef><gtr:id>48FD7E86-327D-4F50-8A5A-F465E4F86331</gtr:id><gtr:outcomeId>56e06d0b710db1.89354832</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>548800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Investigator Award</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B0555D86-D78F-48C6-9B26-5328F65424D8</gtr:id><gtr:outcomeId>56e07007b2f870.48138008</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial collaboration</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Wave Life Sciences</gtr:fundingOrg><gtr:id>A7E6A3D1-A449-416F-8785-D0BACA8CE349</gtr:id><gtr:outcomeId>56e06ec68de0a8.55020798</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European Dermatology Forum</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>62714823-FE4F-442D-9503-C87E91F3CA6C</gtr:id><gtr:outcomeId>kQ4poKLqTSv</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Knock-in mouse expressing human KRT12 gene carrying a dominant-negative mutation under control of the murine Krt12 gene.</gtr:description><gtr:id>F5B708D0-753A-4FFC-986E-539DC86C176A</gtr:id><gtr:impact>Manuscript at advanced stage, submission planned Q4 of 2014.</gtr:impact><gtr:outcomeId>Zr8ktDUFE1X</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K12 humanized knock-in mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Knockout mouse for the palm/sole specific keratin gene Krt9 encoding the K9 protein.</gtr:description><gtr:id>A5CF44A9-7159-4DFA-9B2A-936F46D00CB7</gtr:id><gtr:impact>Paper published in 2013 (on-line) and 2014 (print):

Fu DJ, Thomson C, Lunny DP, Dopping-Hepenstal PJ, McGrath JA, Smith FJD, McLean WHI and Leslie Pedrioli DM (2014) Keratin 9 is Required for the Structural Integrity and Terminal Differentiation of Palmoplantar Epidermis. J Invest Dermatol 134:754-763 [Epub ahead of print Aug 20, 2013] (PubMed ID: 23962810)</gtr:impact><gtr:outcomeId>mD6f5x6MnMJ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K9 knockout mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Expresses luciferase reporter gene under the control of the murine Krt12 gene. Carries multiple human therapy target sequences.</gtr:description><gtr:id>9C2E3087-22CC-4034-98C8-9C171BAB4BD7</gtr:id><gtr:impact>Manuscript at advanced stage, for submission Q4 of 2014.</gtr:impact><gtr:outcomeId>q1oBDGoMNDZ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K12-luciferase knock-in mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Knock-in mouse carrying a dominant-negative mutation in the human KRT9 gene.</gtr:description><gtr:id>6E699926-5510-4286-B762-8370FDF32D6C</gtr:id><gtr:impact>Publication planned 2015.</gtr:impact><gtr:outcomeId>sHKxhagbAMQ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K9 humanized knock-in mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Knock-in mouse expressing luciferase under the control of the murine Krt9 gene. Carries multiple therapy target sequences.</gtr:description><gtr:id>F62063B2-2BD3-4F06-91B7-E01A393337A3</gtr:id><gtr:impact>Publication planned 2015.</gtr:impact><gtr:outcomeId>KtYdbnSfhV4</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>K9-luciferase reporter gene mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>525A3444-817F-441E-9158-2A96B5CE6A27</gtr:id><gtr:title>Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0b724864d8662282599ac1a61ce0048"><gtr:id>e0b724864d8662282599ac1a61ce0048</gtr:id><gtr:otherNames>Fu T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>djSP53PsSvx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA420E9E-EE9B-4FBE-8F0C-D7BAECFA998E</gtr:id><gtr:title>A large mutational study in pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee30dd370782ce25fab3dc90f4cebcf9"><gtr:id>ee30dd370782ce25fab3dc90f4cebcf9</gtr:id><gtr:otherNames>Wilson NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>gFGgJ1QUxxH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1F0A15C-462C-4179-B1D1-36FD7D61EBFE</gtr:id><gtr:title>An appraisal of oral retinoids in the treatment of pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>Journal of the American Academy of Dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ab370a86694fb9ee878ce474bfb70c8"><gtr:id>6ab370a86694fb9ee878ce474bfb70c8</gtr:id><gtr:otherNames>Gruber R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0190-9622</gtr:issn><gtr:outcomeId>tUV6qTaVymY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE959B4F-E12F-44F2-B4CA-609DF6FD5857</gtr:id><gtr:title>Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/295b4174b3be6efaa8ef6f5395c1e78e"><gtr:id>295b4174b3be6efaa8ef6f5395c1e78e</gtr:id><gtr:otherNames>Spaunhurst KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>MwHNyvsX2Lt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BD4C169-8429-47FF-8BA6-07B828E349DB</gtr:id><gtr:title>First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33c495952b4fc5fe6774d1b49df82ab2"><gtr:id>33c495952b4fc5fe6774d1b49df82ab2</gtr:id><gtr:otherNames>Leachman SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>4A6D182AA8D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>429BD219-AA12-4EB4-915A-616F286B8219</gtr:id><gtr:title>CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f942453d6b751e05bcbf8b025afdc00"><gtr:id>6f942453d6b751e05bcbf8b025afdc00</gtr:id><gtr:otherNames>Courtney DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>56e06821c558c8.47596124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EA2594A-011C-4553-85C3-DD1ECBEC277F</gtr:id><gtr:title>Novel molecular therapies for heritable skin disorders.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68e09d03badf2c6a33c71d30993b5c56"><gtr:id>68e09d03badf2c6a33c71d30993b5c56</gtr:id><gtr:otherNames>Uitto J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>pm_15081_21_22158553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A604D072-9585-484E-8599-A115175BEB67</gtr:id><gtr:title>Siglec-E promotes ?2-integrin-dependent NADPH oxidase activation to suppress neutrophil recruitment to the lung.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5877cc27b23379ab70ae407e8deaf272"><gtr:id>5877cc27b23379ab70ae407e8deaf272</gtr:id><gtr:otherNames>McMillan SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>54624351b17f29.62999113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87F3BEC4-32F0-4A6D-B696-9D33436026E7</gtr:id><gtr:title>Keratin 9 is required for the structural integrity and terminal differentiation of the palmoplantar epidermis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fab822d9ac530e6c1b15c67b06ed981"><gtr:id>1fab822d9ac530e6c1b15c67b06ed981</gtr:id><gtr:otherNames>Fu DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>pm_15081_21_23962810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61733108-6CCD-4C1F-849F-3F8FD336D543</gtr:id><gtr:title>Development of quantitative molecular clinical end points for siRNA clinical trials.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb2b3892d790bb4dcf1068f75965dad2"><gtr:id>bb2b3892d790bb4dcf1068f75965dad2</gtr:id><gtr:otherNames>Hickerson RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>gHtWUex3TGe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DEDEA1F-8ED5-4510-BAE0-C0B419D3C43B</gtr:id><gtr:title>Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b694ac73ae81bc1d9795abb4ece7cd7"><gtr:id>9b694ac73ae81bc1d9795abb4ece7cd7</gtr:id><gtr:otherNames>Leslie Pedrioli DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>pm_15081_21_22402445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>445AE1A1-4491-4922-8E09-54F76F25F3BF</gtr:id><gtr:title>In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d41aaa72233ee1310e41f89d5608b9b2"><gtr:id>d41aaa72233ee1310e41f89d5608b9b2</gtr:id><gtr:otherNames>Hegde V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>doi_55f9859850a45061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D0B1EA6-7F37-48EC-90DB-BBB00D72CB05</gtr:id><gtr:title>Increased pachyonychia congenita severity in patients with concurrent keratin and filaggrin mutations.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ab370a86694fb9ee878ce474bfb70c8"><gtr:id>6ab370a86694fb9ee878ce474bfb70c8</gtr:id><gtr:otherNames>Gruber R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>BmfTK3LPV8M</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B9DCE86-20D8-4A57-8D84-A610C5D241E7</gtr:id><gtr:title>Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d59f85b8e3d5471bf73b246942c201b"><gtr:id>7d59f85b8e3d5471bf73b246942c201b</gtr:id><gtr:otherNames>Liao H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15081_21_22174841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>774A65F3-2D55-4E4D-AB8C-8B45D06E4FDF</gtr:id><gtr:title>Jitter reduction using native fiducials in rotating mirror ultra-fast microphotography.</gtr:title><gtr:parentPublicationTitle>Optics express</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c3ec7af48633e750a4fd59ab453af5a"><gtr:id>3c3ec7af48633e750a4fd59ab453af5a</gtr:id><gtr:otherNames>Goh BH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1094-4087</gtr:issn><gtr:outcomeId>56e0681f081f41.38497073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A057420-CC0D-41B9-99F5-784275036D43</gtr:id><gtr:title>Toward a treatment for pachyonychia congenita: report on the 7th Annual International Pachyonychia Congenita Consortium meeting.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08106e20b29c075afbbad3226ae231ed"><gtr:id>08106e20b29c075afbbad3226ae231ed</gtr:id><gtr:otherNames>Kaspar RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>hoW9MGaUmhi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA64F18E-471B-4AA5-8678-23EEB4B4FCED</gtr:id><gtr:title>A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed63a9d2ecf893de047b88ad09ec4f4a"><gtr:id>ed63a9d2ecf893de047b88ad09ec4f4a</gtr:id><gtr:otherNames>McElroy SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>pm_15081_21_23824517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78EB936B-6E93-4E9B-BF55-4B2067013917</gtr:id><gtr:title>Achieving successful delivery of nucleic acids to skin: 6th Annual Meeting of the International Pachyonychia Congenita Consortium.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08106e20b29c075afbbad3226ae231ed"><gtr:id>08106e20b29c075afbbad3226ae231ed</gtr:id><gtr:otherNames>Kaspar RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>sLL3rsj4xsL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3301E1AF-4283-45B1-94C2-EFB5B5B6686A</gtr:id><gtr:title>Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5254897cc9e93a3e7d85addac987a800"><gtr:id>5254897cc9e93a3e7d85addac987a800</gtr:id><gtr:otherNames>Allen EHA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>pm_15081_21_23233254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B0FF599-0927-4965-A627-4590650BB52F</gtr:id><gtr:title>The phenotypic and molecular genetic features of pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a06ac4c15fa5ab9d9f15bd95c259659"><gtr:id>1a06ac4c15fa5ab9d9f15bd95c259659</gtr:id><gtr:otherNames>McLean WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>JYAXGqiVqYo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96E8A9D9-7941-4944-A383-A7ED08AFA593</gtr:id><gtr:title>Keratin disorders: from gene to therapy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a06ac4c15fa5ab9d9f15bd95c259659"><gtr:id>1a06ac4c15fa5ab9d9f15bd95c259659</gtr:id><gtr:otherNames>McLean WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>EgexmtnugkR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E26358DB-EA9F-4315-B32C-008599471D2D</gtr:id><gtr:title>Generation and characterisation of keratin 7 (K7) knockout mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55b03925a89ecafca13d607e205db131"><gtr:id>55b03925a89ecafca13d607e205db131</gtr:id><gtr:otherNames>Sandilands A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15081_21_23741325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBBA2118-33DD-4FDE-A456-0AAD22606F41</gtr:id><gtr:title>Keratin 12 missense mutation induces the unfolded protein response and apoptosis in Meesmann epithelial corneal dystrophy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c89a5fb166c140e6fb30bd0d146c474"><gtr:id>9c89a5fb166c140e6fb30bd0d146c474</gtr:id><gtr:otherNames>Allen EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56e068223a13d7.30543920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68417E50-0726-48F2-A960-FF73BCF7A81C</gtr:id><gtr:title>Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11fed8cbe5d1835e8044215728332a22"><gtr:id>11fed8cbe5d1835e8044215728332a22</gtr:id><gtr:otherNames>Atkinson SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>ByAETrv9nPL</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801742</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>